Hemato Oncology Testing Market Size & Share 2024 – 2032
Market Size by Product & Service (Instrument {PCR, NGS}, Kits & Reagents, Software & Service), Cancer Type (Leukemia {Acute Myeloid, Acute Lymphoblastic}, Lymphoma {Hodgkin, Non-Hodgkin}).
Report ID: GMI10902
|
Published Date: August 2024
|
Report Format: PDF
Download Free PDF
Authors:
Monali Tayade, Jignesh Rawal
Hemato Oncology Testing Market Size
Hemato Oncology Testing Market size was valued at USD 3.2 billion in 2023 growing at a CAGR of 14.2% from 2024 to 2032. The market's growth is primarily fueled by the rising prevalence of hematological malignancies, such as myeloma and lymphoma, driving an increased demand for specialized diagnostic tests.
Hemato Oncology Testing Market Key Takeaways
Market Size & Growth
Key Market Drivers
Challenges
For example, a report from the American Cancer Society highlights that non-Hodgkin lymphoma (NHL) ranks among the most prevalent cancers in the U.S., constituting roughly 4% of all cancer cases. Moreover, the report notes that in 2023, approximately 80,620 individuals (44,590 males and 36,030 females) received NHL diagnosis. Consequently, advancements in diagnostic technology, coupled with heightened awareness of hematologic cancers and the advantages of early detection, have spurred a rise in screening and diagnostic testing, further propelling the market's growth.
Hemato oncology testing is a specialized medical diagnostic field dedicated to detecting, diagnosing, and monitoring blood-related cancers, including leukemia, lymphoma, and multiple myeloma. These tests aim to pinpoint genetic mutations, chromosomal abnormalities, and other biomarkers linked to hematologic malignancies.
Hemato Oncology Testing Market Trends
Innovations in molecular diagnostic technologies, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and fluorescence in situ hybridization (FISH), have improved the accuracy and speed of hemato oncology testing, driving market growth during the analysis period. For example, the National Comprehensive Cancer Network and the European LeukemiaNet guidelines for chronic myelogenous leukemia (CML) endorse the RT-qPCR test for diagnosis confirmation. They recommend the RT-qPCR test every 3 months until BCR-ABL1 transcripts drop below 0.1%, then every 3 to 6 months. This increases the use of PCR-based assays, given their high sensitivity in detecting genetic mutations in patient blood samples and bone marrow. Furthermore, advancements in diagnostic technology facilitate personalized medicine approaches, increasing the demand for hemato-oncology testing and contributing to market growth.
Hemato Oncology Testing Market Analysis
Based on the product & service, the market is classified into instrument, kits & reagents, and software & services. The instrument is further bifurcated into next generation sequencing (NGS), polymerase chain reaction (PCR), flow cytometry, cytogenetics, immunohistochemistry, and other technologies. The kits & reagents segment dominated the market with revenue of USD 1.7 billion in 2023.
Based on the cancer type, the global hemato oncology testing market is segmented into leukemia, lymphoma, and other cancer types. The leukemia is further bifurcated into acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML). The lymphoma is sub-segmented into Hodgkin lymphoma, and non-Hodgkin lymphoma. The lymphoma segment dominated the market with market share of 51.3% in 2023.
Based on end-use, the hemato oncology testing market is classified into hospitals & clinics, diagnostic laboratories, and other end-users. The diagnostic laboratories segment is expected to exhibit 14.5% CAGR between 2024-2032.
In 2023, North America held a commanding 45.6% share of the global hemato oncology testing market, a trend poised to continue throughout the forecast period.
These factors solidify North America's leading position in the hemato oncology testing market.
The U.S. hemato-oncology testing market is projected to grow at a robust CAGR of 14.1% from 2024 to 2032.
Germany is set to lead the growth in Europe's hemato oncology testing market.
The Asia Pacific region anticipates a notable CAGR of 14.7% in its hemato oncology testing market during the forecast period.
Hemato Oncology Testing Market Share
The market is characterized by intense competition among key players aiming to expand their market presence. Leading companies are focusing on strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their market position. These efforts are aimed at enhancing their product and service offerings, expanding their geographic reach, and investing in advanced technologies. The market also witnesses the entry of new players, intensifying the competitive landscape further.
Hemato Oncology Testing Market Companies
Prominent players operating in the hemato oncology testing industry are as mentioned below:
Hemato Oncology Testing Industry News:
The hemato oncology testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:
Click here to Buy Section of this Report
Market, By Product & Service
Market, By Cancer Type
Market, By End-use
The above information is provided for the following regions and countries:
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →